AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34520295 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation-focused intervention (cognitive restructuring or mindfulness) with alcohol (target peak BrAC = .08%)
Number of subjects: 299
Study 34520295 — intervention group
Group type: COMPARATOR
Intervention: Control group with alcohol (target peak BrAC = .08%)
Number of subjects: 299
Study 34520295 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation-focused intervention (cognitive restructuring or mindfulness) with nonalcoholic beverage
Number of subjects: 299
Study 34520295 — intervention group
Group type: COMPARATOR
Intervention: Control group with nonalcoholic beverage
Number of subjects: 299
Study 32077231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg ZGN-1061
Number of subjects: 0
Study 32077231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg ZGN-1061
Number of subjects: 0
Study 32077231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35227636 — intervention group
Group type: EXPERIMENTAL
Intervention: Text format of risk communication
Number of subjects: 60
Study 35227636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram format of risk communication
Number of subjects: 60
Study 35227636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cube diagram format of risk communication
Number of subjects: 60
Study 33413713 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow cassava (YC)
Number of subjects: 176
Study 33413713 — intervention group
Group type: COMPARATOR
Intervention: White cassava (WC)
Number of subjects: 176
Study 35874986 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based CPR plan
Number of subjects: 43
Study 35596803 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg/day
Number of subjects: 60
Study 35596803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33634687 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF) standard dose of 1000 mg once daily for 2 months (group 1)
Number of subjects: 125
Study 33634687 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavonoid fraction (MPFF) double dose of 1000 mg twice daily for 1 month and then 1000 mg once daily for 1 month (group 2)
Number of subjects: 125
Study 32110939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual compression stockings (GCSs)
Number of subjects: 16
Study 32110939 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without GCSs)
Number of subjects: 16
Study 36318686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap block in oblique subcostal approach (OSTAP)
Number of subjects: 81
Study 36318686 — intervention group
Group type: COMPARATOR
Intervention: Classic multimodal iv opioid analgesia
Number of subjects: 81
Study 36318686 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration of the trocar insertion sites (LAI)
Number of subjects: 81
Study 33735635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose oil softgel
Number of subjects: 70
Study 33735635 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole capsule
Number of subjects: 70
Study 35783616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (0.4mg/kg per day for 3 days)
Number of subjects: 1158
Study 35783616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1158
Study 32178701 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus injection
Number of subjects: 160
Study 32178701 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhiza injection
Number of subjects: 160
Study 32178701 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 160
Study 32178701 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including treatment and control)
Number of subjects: 160
Study 34167901 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 150
Study 34167901 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 150
Study 32878737 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning (fasting) exercise (MorEx)
Number of subjects: 14
Study 32878737 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon exercise (AftEx)
Number of subjects: 14
Study 32878737 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (EveEx)
Number of subjects: 14
Study 32878737 — intervention group
Group type: COMPARATOR
Intervention: Seated control
Number of subjects: 14
Study 32878737 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (MorEx)
Number of subjects: 14
Study 35125436 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling and 5% 5-Fluorouracil (5-FU)
Number of subjects: 44
Study 35125436 — intervention group
Group type: COMPARATOR
Intervention: Microneedling and 0.5% 5-Fluorouracil (5-FU)
Number of subjects: 44
Study 35125436 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-Fluorouracil (5-FU) alone
Number of subjects: 44
Study 34830950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated RT/stereotactic body RT with focal RT dose escalation on intraprostatic tumor sides
Number of subjects: 0
Study 34830950 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypofractionated RT (MHRT)
Number of subjects: 0
Study 34830950 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 0
Study 35432383 — intervention group
Group type: EXPERIMENTAL
Intervention: VACCIMEL plus BCG and GM-CSF
Number of subjects: 30
Study 35432383 — intervention group
Group type: COMPARATOR
Intervention: IFNα2b
Number of subjects: 30
Study 35432383 — intervention group
Group type: EXPERIMENTAL
Intervention: VACCIMEL
Number of subjects: 30
Study 36289039 — intervention group
Group type: EXPERIMENTAL
Intervention: Physics Direct Patient Care (PDPC)
Number of subjects: 66
Study 36289039 — intervention group
Group type: COMPARATOR
Intervention: Control (standard radiation therapy workflow)
Number of subjects: 66
Study 33527809 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan 40 mg
Number of subjects: 303
Study 33527809 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan 80 mg
Number of subjects: 303
Study 33527809 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 40 mg
Number of subjects: 303
Study 32232767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-component molecular assay (mutation analysis and miR-146b-5p assay)
Number of subjects: 156
Study 32232767 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of mutation analysis and miR-146b-5p assay
Number of subjects: 156
Study 35932889 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate telephone smoking cessation intervention (TSI) support with appropriate pharmacotherapy for 6 weeks
Number of subjects: 315
Study 35932889 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; very brief advice to quit and signposting to smoking cessation services)
Number of subjects: 315
Study 33594133 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 20 Hz (alpha)
Number of subjects: 0
Study 33594133 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 10 Hz (beta)
Number of subjects: 0
Study 33594133 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (30 s of low-frequency transcranial random noise stimulation; tRNS)
Number of subjects: 0
Study 33594133 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 10 Hz (alpha)
Number of subjects: 0
Study 33594133 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS at 20 Hz (beta)
Number of subjects: 0
Study 32532781 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill intervention
Number of subjects: 300
Study 32532781 — intervention group
Group type: COMPARATOR
Intervention: Control (standard practice)
Number of subjects: 300
Study 34203476 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube (ETT)
Number of subjects: 45
Study 34203476 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 45
Study 32544067 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mm group
Number of subjects: 50
Study 32544067 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mm group
Number of subjects: 50
Study 32544067 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm group
Number of subjects: 50
Study 35000860 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetic peripheral neuropathy
Number of subjects: 165
Study 35000860 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean HDL/LDL cholesterol ratio
Number of subjects: 165
Study 33774634 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 28
Study 33774634 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 32381843 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 51
Study 32381843 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and doxycycline
Number of subjects: 51
Study 32381843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 35942626 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding valve (SEV)
Number of subjects: 416
Study 35942626 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable valve (BEV)
Number of subjects: 416
Study 34945036 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh direct laryngoscope (MAC) without PPE
Number of subjects: 54
Study 36305040 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP with coverage of 70%
Number of subjects: 0
Study 36305040 — intervention group
Group type: COMPARATOR
Intervention: Control (no PrEP)
Number of subjects: 0
Study 32888250 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based weight-loss intervention
Number of subjects: 370
Study 32888250 — intervention group
Group type: COMPARATOR
Intervention: Standard WIC
Number of subjects: 370
Study 35039299 — intervention group
Group type: EXPERIMENTAL
Intervention: Zemedy app (CBT-based smartphone app)
Number of subjects: 300
Study 35039299 — intervention group
Group type: COMPARATOR
Intervention: Active control app (education and relaxation training)
Number of subjects: 300
Study 32931635 — intervention group
Group type: EXPERIMENTAL
Intervention: Otsu thresholding
Number of subjects: 45
Study 32931635 — intervention group
Group type: COMPARATOR
Intervention: 3.3 SD above BP mean intensity
Number of subjects: 45
Study 32931635 — intervention group
Group type: COMPARATOR
Intervention: IIR above 1.61
Number of subjects: 45
Study 32931635 — intervention group
Group type: COMPARATOR
Intervention: Texture analysis for voxels above the 70th percentile
Number of subjects: 45
Study 35233724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy meal replacement plan (≈ 810 kcal/day)
Number of subjects: 90
Study 35233724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 90
Study 35233724 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 90
Study 33521132 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine therapy
Number of subjects: 1455
Study 32830463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Janus kinase 1 (JAK1) inhibitor abrocitinib (dose range 10-200 mg)
Number of subjects: 0
Study 32830463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36242741 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium (45 mg for 14 days)
Number of subjects: 223
Study 36242741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 33218118 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed piezoelectric tactile sensor for tissue stiffness detection
Number of subjects: 5
Study 33218118 — intervention group
Group type: COMPARATOR
Intervention: Unoptimized sensor
Number of subjects: 5
Study 36215714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy screening
Number of subjects: 274952
Study 36215714 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274952
Study 33823960 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related behavioral activation (F-BA) therapy with placebo supplements
Number of subjects: 933
Study 33823960 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplements (omega-3 fatty acids and a multi-vitamin)
Number of subjects: 933
Study 33823960 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 933
Study 33823960 — intervention group
Group type: EXPERIMENTAL
Intervention: F-BA therapy with multi-nutrient supplements
Number of subjects: 933
Study 35760971 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion of piperacillin/tazobactam
Number of subjects: 53
Study 35760971 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin/tazobactam
Number of subjects: 53
Study 35760971 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 53
Study 33320397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Patient Education combined with active individualized physiotherapy (COPE‐PT)
Number of subjects: 128
Study 33320397 — intervention group
Group type: COMPARATOR
Intervention: Norwegian Psychomotor Physiotherapy (NPMP)
Number of subjects: 128
Study 34634975 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients with low health literacy
Number of subjects: 301
Study 34634975 — intervention group
Group type: COMPARATOR
Intervention: English-speaking patients with low health literacy
Number of subjects: 301
Study 34634975 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish speakers
Number of subjects: 301
Study 34634975 — intervention group
Group type: COMPARATOR
Intervention: English speakers
Number of subjects: 301
Study 34913186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg every 4 weeks
Number of subjects: 550
Study 34913186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (pooled cohort)
Number of subjects: 550
Study 34913186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study 32664997 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceroceptive interventions focusing on areas pertaining to the gut or heart, running for 8 weeks.
Number of subjects: 0
Study 32664997 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial cueing task measuring reaction times to bodily changes relating to lower abdomen or chest focus.
Number of subjects: 0
Study 32664997 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop/signal task measuring emotional inhibition.
Number of subjects: 0
Study 32664997 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartbeat estimation task, water load test, and self-report questionnaire to track visceroceptive ability.
Number of subjects: 0
Study 32664997 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 34519614 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter campaign
Number of subjects: 702
Study 34519614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Twitter campaign)
Number of subjects: 702
Study 34519614 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior year's flu shot
Number of subjects: 702
Study 34519614 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital social network structure
Number of subjects: 702
Study 34398235 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 120
Study 34398235 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 120
Study 34398235 — intervention group
Group type: COMPARATOR
Intervention: Varenicline vs Nicotine patches
Number of subjects: 120
Study 33060783 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal acid infusion
Number of subjects: 0
Study 33060783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33060783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mast cell stabilizer disodiumcromoglycate (DSCG)
Number of subjects: 0
Study 33060783 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 35164741 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated picture book group
Number of subjects: 131
Study 35164741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study 35164741 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 131
Study 33997052 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment prior to restoration
Number of subjects: 48
Study 33997052 — intervention group
Group type: COMPARATOR
Intervention: Nanohybrid composite resin (CR)
Number of subjects: 48
Study 33997052 — intervention group
Group type: COMPARATOR
Intervention: Resin‐modified glass ionomer (RMGI)
Number of subjects: 48
Study 33997052 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer (GIC)
Number of subjects: 48
Study 33372080 — intervention group
Group type: EXPERIMENTAL
Intervention: Open technique
Number of subjects: 100
Study 33372080 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic technique
Number of subjects: 100
Study 34988851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) prophylaxis
Number of subjects: 102
Study 34988851 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 102
Study 33044435 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise (150 min·wk‐1)
Number of subjects: 125
Study 33044435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (300 min·wk‐1)
Number of subjects: 125
Study 33044435 — intervention group
Group type: COMPARATOR
Intervention: Control (<75 min·wk‐1)
Number of subjects: 125
Study 35358372 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRCs
Number of subjects: 88
Study 35358372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 35358372 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRCs (dcSSc)
Number of subjects: 88
Study 32294652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine and Dexamethasone (VD group)
Number of subjects: 60
Study 32294652 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (D group)
Number of subjects: 60
Study 32659483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nVNS (0–30 V, 25 Hz, pulse width = 40 ms)
Number of subjects: 19
Study 32659483 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (0–14 V, 0.2 Hz, pulse width = 5s)
Number of subjects: 19
Study 35299272 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines (IHM) in centesimal potencies
Number of subjects: 126
Study 35299272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 126
Study 33642331 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane microcuff ETT with pressure volume loop
Number of subjects: 80
Study 33642331 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane microcuff ETT with audible leak
Number of subjects: 80
Study 33642331 — intervention group
Group type: COMPARATOR
Intervention: PVC ETT with pressure volume loop
Number of subjects: 80
Study 33642331 — intervention group
Group type: COMPARATOR
Intervention: PVC ETT with audible leak
Number of subjects: 80
Study 35916848 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded sensorimotor retraining intervention (RESOLVE)
Number of subjects: 276
Study 35916848 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure and attention control
Number of subjects: 276
Study 35916848 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 276
Study 33576129 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 450
Study 33576129 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 450
Study 35379642 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) integrated into online laboratory ordering system
Number of subjects: 9683
Study 35379642 — intervention group
Group type: COMPARATOR
Intervention: Usual lab ordering system (Control)
Number of subjects: 9683
Study 34182967 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) with a diode laser (810 nm wavelength, 100 mW power output, 6.29 J/cm2 energy density) applied on days 0, 7, 14, and 21 after loading the canine retraction forces.
Number of subjects: 12
Study 34182967 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 12
Study 33322157 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom movement breaks (CMBs) of 15-min with different degrees of difficulty
Number of subjects: 49
Study 33322157 — intervention group
Group type: EXPERIMENTAL
Intervention: CMBs with optimal cognitive difficulty
Number of subjects: 49
Study 36160152 — intervention group
Group type: EXPERIMENTAL
Intervention: P2Et
Number of subjects: 0
Study 36160152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35633183 — intervention group
Group type: EXPERIMENTAL
Intervention: All-ceramic crowns on zirconia abutments (AC)
Number of subjects: 30
Study 35633183 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns on metal abutments (MC)
Number of subjects: 30
Study 35633183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using OHIP-49 questionnaire
Number of subjects: 30
Study 33483450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Home Visiting (NHV) program (right@home) with 25 home visits until child age 2 years
Number of subjects: 722
Study 33483450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 722
Study 33901552 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (cACB)
Number of subjects: 60
Study 33901552 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (cFNB)
Number of subjects: 60
Study 34033811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation of occiput posterior or occiput transverse position
Number of subjects: 257
Study 34033811 — intervention group
Group type: COMPARATOR
Intervention: No trial of prophylactic manual rotation (standard group)
Number of subjects: 257